Pablo Pergola, MD
Nephrology · San Antonio, TXNPI 1902872765
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $132,101 of the $163,918 with a category attached, or 80.6%. 27 manufacturers reported payments, led by AstraZeneca at 30.5% of the total. Reporting peaked in 2024 at $46,562 and has fallen 85.4% since, to $6,792 in 2025. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $591.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$50K
- Bayer$23K
- Akebia Therapeutics Inc$18K
- Novo Nordisk$17K
- GSK$16K
- Gilead$15K
- plus $25K from 21 others
Across 3,776 payments — averaging $3771.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$2.8M
- Bayer$2.6M
- AstraZeneca$2.2M
- Astrazeneca UK Limited$1.7M
- GSK$1M
- Gilead$757K
- plus $3.2M from 21 others
What the payments were for
- Consulting fees$132,10181%
- Speaking & faculty fees$9,1186%
- Travel & lodging$15,82810%
- Food & beverage$6,8374%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 72 | $50,042 |
| Bayer | 61 | $22,769 |
| Akebia Therapeutics Inc | 10 | $17,654 |
| Novo Nordisk | 24 | $16,784 |
| GSK | 11 | $15,950 |
| Gilead | 7 | $15,395 |
| Ardelyx, Inc. | 8 | $10,237 |
| Novo Nordisk AS | 3 | $4,275 |
| Boehringer Ingelheim International GmbH | 3 | $2,368 |
| Scpharmaceuticals Inc. | 1 | $2,000 |
| Boehringer Ingelheim | 6 | $1,827 |
| CSL Behring | 1 | $1,779 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,173 |
| Astrazeneca UK Limited | 5 | $394 |
| Amgen(2 entities) | 15 | $251 |
| Vifor Pharma, Inc. | 15 | $243 |
| Fennec Pharmaceuticals, Inc. | 1 | $121 |
| Novartis | 6 | $116 |
| Lilly USA, LLC | 5 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Fresenius USA Marketing, Inc. | 5 | $88 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Aurinia Pharma U.S., Inc. | 2 | $59 |
| Travere Therapeutics, Inc. | 4 | $58 |
| ANI Pharmaceuticals, Inc. | 1 | $34 |
| Johnson & Johnson | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$163,918 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 203 | $269,045 |
| FarxigaDapagliflozin Propanediol | 100 | $98,323 |
| TrulicityDulaglutide | 73 | $92,354 |
| OzempicSemaglutide | 53 | $58,819 |
| Bydureon BciseExenatide Microspheres | 19 | $42,743 |
| VelphoroSucroferric Oxyhydroxide | 12 | $40,427 |
| EntrestoSacubitril/Valsartan | 11 | $21,322 |
| EliquisApixaban | 12 | $13,238 |
| InvokanaCanagliflozin | 12 | $11,267 |
| Candesartan Cilexetil | 77 | $4,227 |
| Doxazosin Mesylate | 84 | $1,168 |
| Allopurinol | 88 | $1,103 |
| Pentoxifylline | 23 | $929 |
| Valsartan | 21 | $909 |
| Hydralazine Hcl | 44 | $617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $1,827 | $269,045203 claims |
| AstraZenecaFarxiga | $50,042 | $98,323100 claims |
| Lilly USA, LLCTrulicity | $111 | $92,35473 claims |
| Novo NordiskOzempic | $16,784 | $58,81953 claims |
| Fresenius USA Marketing, Inc.Velphoro | $88 | $40,42712 claims |
| NovartisEntresto | $116 | $21,32211 claims |
| Johnson & JohnsonInvokana | $16 | $11,26712 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $34 | $90921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in San Antonio
- Luis VelezSan Antonio$505K
- Rashid SharafSan Antonio$340K
- Carl DukesSan Antonio$238K
- Varshasb BroumandSan Antonio$118K
- Shweta BansalSan Antonio$89K
- Rajeev NarayanSan Antonio$57K
- Anwar GergesSan Antonio$50K
- Matthew SchaeferSan Antonio$46K
- Kumar SharmaSan Antonio$45K
- Gerardo ChicaSan Antonio$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.